Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Visentin

Showing results (1-10 of 193) with videos related to

Pageof 20
Sort By:
Annals of Hematology|February 10, 2026
Latest advances in frontline CLL treatment from the 2025 ASH congressAndrea Visentin
Frontiers in Immunology|August 18, 2025
Editorial: Immune system interactions in hematological tumor microenvironments: pathways to innovative treatmentsElisa Mandato, Andrea Visentin
Haematologica|November 18, 2021
Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients"Andrea Visentin, Livio Trentin
Frontiers in Oncology|March 5, 2024
Editorial: Covid-19 therapies in patients with hematologic malignanciesAndrea Visentin, Massimo Gentile
Handbook of Clinical Neurology|March 17, 2024
Hematologic malignancies and hematopoietic stem cell transplantationChiara Briani, Andrea Visentin
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 29, 2022
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating NeuropathiesChiara Briani, Andrea Visentin
Handbook of Clinical Neurology|January 12, 2026
Immunotherapies in chronic immune-mediated neuropathiesChiara Briani, Andrea Visentin
Oncology Reviews|January 5, 2026
Lights and shades of front-line treatment with covalent BTK inhibitors combined with venetoclax in patients with chronic lymphocytic leukemiaAndrea Visentin, Francesca R Mauro
Igiene E Sanita Pubblica|July 23, 2025
Hospital Falls: retrospective analysis of risk factors and prevention strategies in a healthcare organization in northern ItalyValentina De Franceschi, Andrea Visentin
Expert Opinion on Investigational Drugs|December 28, 2023
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?Andrea Visentin, Marco Puthenparampil, Chiara Briani
Pageof 20

Showing results (1-10 of 193) with videos related to

Sort By:
Pageof 20
Annals of Hematology|February 10, 2026
Latest advances in frontline CLL treatment from the 2025 ASH congressAndrea Visentin
Frontiers in Immunology|August 18, 2025
Editorial: Immune system interactions in hematological tumor microenvironments: pathways to innovative treatmentsElisa Mandato, Andrea Visentin
Haematologica|November 18, 2021
Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients"Andrea Visentin, Livio Trentin
Frontiers in Oncology|March 5, 2024
Editorial: Covid-19 therapies in patients with hematologic malignanciesAndrea Visentin, Massimo Gentile
Handbook of Clinical Neurology|March 17, 2024
Hematologic malignancies and hematopoietic stem cell transplantationChiara Briani, Andrea Visentin
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 29, 2022
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating NeuropathiesChiara Briani, Andrea Visentin
Handbook of Clinical Neurology|January 12, 2026
Immunotherapies in chronic immune-mediated neuropathiesChiara Briani, Andrea Visentin
Oncology Reviews|January 5, 2026
Lights and shades of front-line treatment with covalent BTK inhibitors combined with venetoclax in patients with chronic lymphocytic leukemiaAndrea Visentin, Francesca R Mauro
Igiene E Sanita Pubblica|July 23, 2025
Hospital Falls: retrospective analysis of risk factors and prevention strategies in a healthcare organization in northern ItalyValentina De Franceschi, Andrea Visentin
Expert Opinion on Investigational Drugs|December 28, 2023
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?Andrea Visentin, Marco Puthenparampil, Chiara Briani
Pageof 20